Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News T-Mobile US Inc. TMUS

Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile US. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:TMUS)

Fundamentals Snapshot (NDAQ:TMUS)

Opinion & Analysis (NDAQ:TMUS)

High-Yield Bond ETFs Grapple Higher

Benzinga.com  April 16, 2015

Bullboard Posts (NDAQ:TMUS)

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent

   
MarcLee - July 15, 2022

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

<< View Post To Watch Video >> FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets...
MarcLee - June 3, 2022

FSD Pharma Files Investigational New Drug Application “IND”

 
MarcLee - June 2, 2022

FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets

 
MarcLee - May 11, 2022

Lucid-MS for Multiple Sclerosis Treatment

<< View Post To Watch Video >>
MarcLee - May 2, 2022

"Julia Levy Award" Recipient David Allan and Dr. John McGraw

 
MarcLee - April 25, 2022